<DOC>
	<DOCNO>NCT01496313</DOCNO>
	<brief_summary>The purpose study give patient medullary thyroid cancer either 300mg/day 150mg/day vandetanib compare well dose affect cancer respond . It also help investigator understand side effect different dos patient .</brief_summary>
	<brief_title>To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer</brief_title>
	<detailed_description>An International , Randomised , Double-Blind , Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Written consent Female male patient age 18 year . Previously confirm histological diagnosis unresectable , locally advanced metastatic , hereditary sporadic MTC Objective disease progression within previous 14 month prior enrolment , and/or Have one symptom Investigator believe related patient 's MTC . World Health Organisation ( WHO ) Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 . Has measurable disease ( least one lesion , irradiate within 12 week study randomisation , long diameter equal 10mm ( lymph node minimum equal 15 mm ) CT MRI ) . Lesions must amenable accurate repeat measurement . Prior treatment ( major surgery , radiation therapy , chemotherapy , investigational drug ) receive within 28 day randomization . Abnormal liver function test ( bilirubin 1.5xULRR , ALT , AST , ALP 2.5xULRR 5.0xULRR relate liver metastasis ) . Significant cardiac condition event reduce cardiac function , symptomatic cardiac arrhythmia require treatment , congenital long QT syndrome , history druginduced QT prolongation , QTcF correction unmeasurable 450 ms. Abnormal electrolytes potassium , magnesium calcium , abnormal organ function decrease creatinine clearance . For woman currently pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>medullary thyroid cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>thyroid cancer</keyword>
	<keyword>carcinoma thyroid</keyword>
	<keyword>receptor tyrosine kinase inhibitor</keyword>
	<keyword>VEGFR</keyword>
	<keyword>Unresectable locally advanced thyroid cancer</keyword>
</DOC>